The reporter recently learned from the Ningxia Department of Science and Technology that since Ningxia started the consistency evaluation of generic drugs in 2016, the development of the pharmaceutical industry has been progressing rapidly. In particular, the diabetes prevention and treatment drug "Haochang calcium dobesilate capsule" took the lead in completing the consistency evaluation among the domestic drugs of this variety, and the product sales rose from the fourth place to the first place in the national market, accounting for 35.8%. "The implementation of the consistency evaluation of generic drugs not only ensures the safety and efficacy of domestic generic drugs replacing imported drugs, but also improves the quality of generic drugs and the overall development level of pharmaceutical enterprises in China, safeguarding the lives and health of the general public." Zhang Lei, Director of the Social Development Science and Technology Department of the Ningxia Department of Science and Technology, introduced that in recent years, Ningxia has strengthened policy guidance, enabling pharmaceutical enterprises to unleash innovative vitality. The department takes the lead in collaborating with the Finance Department and the Drug Administration of the autonomous region to extensively solicit the scientific and technological innovation needs of pharmaceutical enterprises, revise relevant subsidy methods, and provide a subsidy of 2 million yuan in batches for each drug that has passed the consistency evaluation of generic drugs and obtained supplementary registration approval or registration approval from the National Drug Administration. At the same time, the technology management department is deeply involved in industrial parks and some pharmaceutical companies, providing "face-to-face" technology services for conducting consistency evaluation of generic drugs. Through multi-channel support such as technology projects, platforms, and talents, Ningxia pharmaceutical companies have continuously enhanced their pharmaceutical research and development capabilities. As of now, the number of drugs that have passed the national quality and efficacy consistency evaluation and obtained registration approvals from the National Medical Products Administration has increased to 10, indicating that pharmaceutical companies have obtained the "entry ticket" to enter the national centralized procurement drug list. In 2023, 14 enterprises in Ningxia applied for the conformity evaluation project of generic drugs, reaching a new high in previous years. The pharmaceutical companies in the autonomous region that have been approved for national generic drug consistency evaluation have cumulatively invested over 97 million yuan in independent research and development expenses. On the one hand, the market competitiveness of enterprises is steadily improving; On the other hand, the burden of medication on the public has been significantly reduced. Among them, the national drug centralized procurement was selected for the generic drug "Somatostatin for Injection", with a single unit price of 12.78 yuan, greatly reducing the cost of clinical application medication. (Lixin News Agency) (Reporter Wang Yingxia, Correspondent He Ling)